

## **SARS-CoV-2 shedding and evolution in immunocompromised hosts during the Omicron period: a multicenter prospective analysis**

Running Title: SARS-CoV-2 in immunocompromised hosts

### **Authors and Affiliations:**

- (1) Zoe Raglow, MD  
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan  
Email: [zoraglow@med.umich.edu](mailto:zoraglow@med.umich.edu)
- (2) Diya Surie, MD  
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia  
Email: [kbz2@cdc.gov](mailto:kbz2@cdc.gov)
- (3) James D. Chappell, MD, PhD  
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee  
Email: [jim.chappell@vumc.org](mailto:jim.chappell@vumc.org)
- (4) Yuwei Zhu, MD, MS  
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee  
Email: [yuwei.zhu@vumc.org](mailto:yuwei.zhu@vumc.org)
- (5) Emily T. Martin, PhD  
School of Public Health, University of Michigan, Ann Arbor, Michigan  
Email: [etmartin@umich.edu](mailto:etmartin@umich.edu)
- (6) Jennie H. Kwon, DO, MS  
Department of Medicine, Washington University, St. Louis, Missouri  
Email: [j.kwon@wustl.edu](mailto:j.kwon@wustl.edu)
- (7) Anne E. Frosch, MD  
Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota  
Email: [anne.frosch@hcmcd.org](mailto:anne.frosch@hcmcd.org)
- (8) Amira Mohamed, MD  
Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York  
Email: [ammohamed@montefiore.org](mailto:ammohamed@montefiore.org)
- (9) Julie Gilbert  
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan  
Email: [juliegil@umich.edu](mailto:juliegil@umich.edu)
- (10) Emily E. Bendall, PhD  
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan  
Email: [bendalle@umich.edu](mailto:bendalle@umich.edu)

- (11) Auden Bahr  
Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan  
Email: [aubahr@umich.edu](mailto:aubahr@umich.edu)
- (12) Natasha Halasa, MD, MPH  
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee  
Email: [natasha.halasa@vumc.org](mailto:natasha.halasa@vumc.org)
- (13) H. Keipp Talbot, MD, MPH  
Departments of Medicine and Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee  
Email: [keipp.talbot@vumc.org](mailto:keipp.talbot@vumc.org)
- (14) Carlos G. Grijalva, MD, MPH  
Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee  
Email: [carlos.grijalva@vumc.org](mailto:carlos.grijalva@vumc.org)
- (15) Adrienne Baughman  
Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee  
Email: [adrienne.baughman@vumc.org](mailto:adrienne.baughman@vumc.org)
- (16) Kelsey N. Womack, PhD  
Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee  
Email: [kelsey.womack@vumc.org](mailto:kelsey.womack@vumc.org)
- (17) Cassandra Johnson, MS  
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee  
Email: [cassie.johnson@vumc.org](mailto:cassie.johnson@vumc.org)
- (18) Sydney A. Swan, MPH  
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee  
Email: [sa.swan@vumc.org](mailto:sa.swan@vumc.org)
- (19) Emilia Koumans, MD, MPH  
Division of STD Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia  
Email: [exk0@cdc.gov](mailto:exk0@cdc.gov)
- (20) Meredith L. McMorrow, MD, MPH  
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia  
Email: [bwe3@cdc.gov](mailto:bwe3@cdc.gov)
- (21) Jennifer L. Harcourt, PhD  
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia  
Email: [zaq6@cdc.gov](mailto:zaq6@cdc.gov)
- (22) Lydia J. Atherton, DVM, PhD  
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia  
Email: [ibz1@cdc.gov](mailto:ibz1@cdc.gov)

(23) Ashley Burroughs

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

Email: [lmj9@cdc.gov](mailto:lmj9@cdc.gov)

(24) Natalie J. Thornburg, PhD

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

Email: [nax3@cdc.gov](mailto:nax3@cdc.gov)

(25) Wesley H. Self, MD, MPH

Vanderbilt Institute for Clinical and Translational Research and Department of Emergency Medicine and, Vanderbilt University Medical Center, Nashville, Tennessee

Email: [wesley.self@vumc.org](mailto:wesley.self@vumc.org)

(26) Adam S. Lauring, MD, PhD\*

Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan

Email: [alauring@med.umich.edu](mailto:alauring@med.umich.edu)

For the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network

**\*Corresponding Author:**

Adam S. Lauring

1137 Catherine Street, MS2 4742C

Ann Arbor, MI 48109

[alauring@med.umich.edu](mailto:alauring@med.umich.edu)

**Keywords:** SARS-CoV-2; COVID-19; immunocompromise; evolution; prolonged replication

**Abstract Word Count:** 250

**Main Text Word Count:** 4430

1 **ABSTRACT**

2 **Background:** Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict or  
3 source the emergence of highly mutated variants. The types of immunosuppression placing  
4 patients at highest risk for prolonged infection and associated intrahost viral evolution remain  
5 unclear.

6  
7 **Methods:** Adults aged  $\geq 18$  years were enrolled at 5 hospitals and followed from 4/11/2022 –  
8 2/1/2023. Eligible patients were SARS-CoV-2-positive in the previous 14 days and had a  
9 moderate or severely immunocompromising condition or treatment. Nasal specimens were  
10 tested by rRT-PCR every 2–4 weeks until negative in consecutive specimens. Positive specimens  
11 underwent viral culture and whole genome sequencing. A Cox proportional hazards model was  
12 used to assess factors associated with duration of infection.

13  
14 **Results:** We enrolled 150 patients with: B cell malignancy or anti-B cell therapy (n=18), solid  
15 organ or hematopoietic stem cell transplant (SOT/HSCT) (n=59), AIDS (n=5), non-B cell  
16 malignancy (n=23), and autoimmune/autoinflammatory conditions (n=45). Thirty-eight (25%)  
17 were rRT-PCR-positive and 12 (8%) were culture-positive  $\geq 21$  days after initial SARS-CoV-2  
18 detection or illness onset. Patients with B cell dysfunction had longer duration of rRT-PCR-  
19 positivity compared to those with autoimmune/autoinflammatory conditions (aHR 0.32, 95% CI  
20 0.15-0.64). Consensus (>50% frequency) spike mutations were identified in 5 individuals who  
21 were rRT-PCR-positive >56 days; 61% were in the receptor-binding domain (RBD). Mutations  
22 shared by multiple individuals were rare (<5%) in global circulation.

23

24 **Conclusions:** In this cohort, prolonged replication-competent Omicron SARS-CoV-2 infections  
25 were uncommon. Within-host evolutionary rates were similar across patients, but individuals  
26 with infections lasting >56 days accumulated spike mutations, which were distinct from those  
27 seen globally.

## 28 INTRODUCTION

29 Over the past three years, the COVID-19 pandemic has been characterized by the emergence of  
30 highly mutated variants of concern (VOC) with altered transmissibility, virulence, and/or ability  
31 to evade neutralization by therapeutic or vaccine-induced antibodies [1,2].

32 Immunocompromised patients are central to many of the clinical and epidemiologic aspects of  
33 SARS-CoV-2 VOC; they are less protected by vaccines [3,4] and may not develop sufficient  
34 immunity to clear the virus, even in the presence of monoclonal antibodies or antiviral drugs  
35 [5,6].

36  
37 Early studies suggested that many immunocompromised individuals are at risk for prolonged  
38 infection with SARS-CoV-2 [7–9]. Among hospitalized patients, those with  
39 immunocompromising conditions are more likely to have detectable viral RNA and to be viral  
40 culture positive beyond 21 days [10–12]. Individuals with hematologic malignancy [10] and  
41 people living with AIDS [13,14] appear to be at greatest risk for prolonged infection. A large  
42 number of case reports of single [7–9,15–17] and multiple [18–20] patients have documented  
43 that a subset of immunocompromised patients are at risk for very prolonged infections, lasting  
44 hundreds of days. Because nearly all these studies are retrospective, with varying levels of  
45 ascertainment bias, prospective studies are needed to fully define this problem and those most  
46 at risk.

47  
48 While the propagation of novel SARS-CoV-2 mutations is generally limited by host clearance  
49 and the stochastic dynamics of transmission [21–23], extended within-host replication in

50 immunocompromised hosts allows the virus sufficient time to accumulate mutations. If  
51 transmitted [24], these viruses will appear to have evolved at an “accelerated rate” with more  
52 mutations per unit time [25]. The increasing identification of multi-mutational events in  
53 immunocompromised hosts and the abrupt emergence of highly mutated VOC have led to the  
54 hypothesis that the Alpha (B.1.1.7) and Omicron (BA.1) variants, and perhaps other VOCs,  
55 originated during these very prolonged infections within immunocompromised individuals  
56 [9,17,26–28]. This hypothesis is further supported by the selection of immune escape  
57 mutations in immunocompromised patients treated with convalescent plasma [9,26].  
58 Importantly, many of the reported cases of extensive within-host evolution originated in the  
59 pre-Alpha or early Alpha variant era, prior to the introduction of vaccines and more effective  
60 antivirals. It is therefore unclear whether current interventions will limit—or, alternatively,  
61 drive—the evolution of highly mutated variants in these individuals and whether this pattern  
62 will be replayed on the Omicron genetic background.

63  
64 To address ongoing and urgent questions related to SARS-CoV-2 infections in  
65 immunocompromised hosts, we performed prospective surveillance in immunocompromised  
66 inpatients and outpatients diagnosed with Omicron variant SARS-CoV-2 infection. Adult  
67 patients were enrolled at 5 sites in the Investigating Respiratory Viruses in the Acutely Ill (IVY)  
68 Network, a collaboration with the US Centers for Disease Control and Prevention (CDC) [4,29].  
69 Through analysis of detailed clinical, RNA viral load, viral culture, and sequence data from  
70 prospectively collected specimens, we define those most at risk for prolonged infection among

71 the cohort studied, the impact of antiviral treatments, and SARS-CoV-2 evolutionary dynamics  
72 in an immunocompromised population.

73

## 74 **METHODS**

75 This program was determined to be public health surveillance with waiver of participant  
76 informed consent by CDC and institutional review boards at all participating institutions and  
77 was conducted in accordance with applicable CDC policy and federal law (45 C.F.R. part  
78 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq).

79

### 80 ***Participants***

81 Immunocompromised adults aged  $\geq 18$  years with SARS-CoV-2 infection were enrolled from  
82 inpatient and outpatient settings at 5 sites in the IVY Network during April 11 – October 1,  
83 2022. Patients were eligible for the study if they had a positive real-time reverse transcription  
84 PCR (rRT-PCR) test for SARS-CoV-2 within the previous 14 days collected as part of routine  
85 clinical care and a moderately or severely immunocompromising condition  
86 ([https://www.covid19treatmentguidelines.nih.gov/special-](https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/)  
87 [populations/immunocompromised/](https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/)). Enrolled patients were followed until they cleared SARS-  
88 CoV-2, as evidenced by 2 consecutive negative rRT-PCR tests approximately 2 weeks apart.

89

90 Patients were categorized into the following 5 groups based on their underlying  
91 immunosuppression: (1) B cell dysfunction, defined as patients receiving B cell depletion or  
92 chimeric antigen receptor T cell (CAR-T) therapy expected to have current activity on the



93 patient's immune system, and/or those with B cell malignancy or myeloma; (2) solid organ or  
94 hematopoietic stem cell transplant (SOT/HSCT), defined as patients with a history of solid organ  
95 or hematopoietic stem cell transplant and on immunosuppressive therapy; (3) acquired  
96 immune deficiency syndrome (AIDS), defined as patients with HIV and CD4 <200 cells/mcL or an  
97 AIDS-defining illness in the preceding 12 months; (4) malignancy, defined as patients with non-B  
98 cell malignancy on cytotoxic, myelosuppressive, or immunomodulatory chemotherapy; and (5)  
99 autoimmune/autoinflammatory, defined as patients with conditions treated with  
100 immunosuppression and not meeting criteria for another category [30]. See Supplemental  
101 Table 1 for a list of qualifying immunosuppressive medications.

102

### 103 ***Data Collection***

104 Demographic and clinical data were collected from electronic medical record review and  
105 patient (or proxy) interview and included: age, sex, race, ethnicity, underlying medical  
106 conditions, symptoms, COVID-19 vaccination history (vaccine type and dates of each dose), and  
107 treatment history, which captured immunosuppressant medications and treatment for SARS-  
108 CoV-2, including outpatient monoclonal antibody therapy and other antiviral therapies. Day  
109 zero for each patient was defined as the earliest of three dates: symptom onset, first positive  
110 SARS-CoV-2 test for the current episode of infection (included to capture patients with positive  
111 tests prior to study enrollment), or the most recent positive SARS-CoV-2 test that made the  
112 patient eligible for the study. This definition was chosen in order to approximate the true onset  
113 date of infection as closely as possible, as not all patients were symptomatic, and some had  
114 prolonged infection prior to study enrollment.

115

### 116 ***Specimen Collection***

117 Nasal swab specimens were collected from each participant at the time of enrollment and  
118 every 2-4 weeks thereafter until viral RNA-negative by rRT-PCR for two consecutive specimens.  
119 Specimens were initially preserved in viral transport media at 2 – 8°C and shipped to a central  
120 laboratory (Vanderbilt University Medical Center, Nashville, Tennessee) where they were  
121 aliquoted, tested by rRT-PCR, and stored at -70°C [4,29,31]. One aliquot was sent to the  
122 University of Michigan (Ann Arbor, Michigan) for whole genome sequencing and another to the  
123 Centers for Disease Control and Prevention (Atlanta, Georgia) for viral culture.

124

### 125 ***RNA Viral Load and Viral Culture***

126 RNA was extracted from 200µl of specimen transport media using the MagMax Viral/Pathogen  
127 II Nucleic Acid Isolation Kit on a KingFisher instrument, eluted in 50µl water, and stored at  
128 -70°C. Amplification of total and subgenomic (sg) transcripts for nucleocapsid (N) genes was  
129 performed using amplification conditions described previously [31,32].

130

131 Specimens were cultured on Vero E6 cells (NR-54970, BEI Resources) stably overexpressing the  
132 transmembrane protease, serine 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE2)  
133 using a previously described method [33].

134

### 135 ***Viral Genomic Sequencing***

136 Sequencing libraries were prepared using the NEBNext ARTIC SARS-CoV-2 Library Prep Kit and  
137 ARTIC v5.3.2 primer sets [34]. After barcoding, pooled libraries were size selected by gel  
138 extraction and sequenced on an Illumina Nextseq 1000 (P1 flow cell 2x300bp reads).  
139 Sequencing reads were aligned to the Wuhan-Hu-1 reference using BWA-mem v0.7.15 [35].  
140 Primers were trimmed and consensus sequences were generated using iVar v1.2.1 [36]. We  
141 used PANGO and Nextclade to annotate SARS-CoV-2 lineages and clades, respectively [37].  
142 Intrahost single nucleotide variants (iSNV) were identified using iVar [36] with the following  
143 criteria: frequency 0.02-1, p-value  $<1 \times 10^{-5}$ , variant position coverage depth  $>100x$ , variant allele  
144 read depth  $\geq 10$ , variant quality score  $>35$ , and genome completeness  $>95\%$ . We also masked  
145 ambiguous and homoplastic sites [38]. Indels were identified at the consensus ( $>50\%$   
146 frequency) level only. Only iSNV present at frequencies  $>2\%$  were included in subsequent  
147 analyses; this threshold was chosen in order to limit false-positive mutations due to sequencing  
148 errors and/or library preparation. In analyses of within-host evolution, any mutation present at  
149  $\geq 98\%$  frequency in the patient's first sample was excluded in order to limit the contribution  
150 from fixed Omicron-related mutations.  
151  
152 Within-host divergence was calculated as in [39]. The frequencies of each type of mutation  
153 (synonymous, non-synonymous, and stop/nonsense) in each SARS-CoV-2 gene for every patient  
154 were summed. Within-host evolution was evaluated by comparing the first and last positive  
155 collected sample for each patient. The sum of the frequencies was then normalized to the  
156 number of sites available for each type of mutation in order to obtain a per-site viral

157 divergence. The per-site viral divergence was divided by the number of days between specimen  
158 collection and infection onset date (day zero).

159

### 160 ***Neutralization Assays***

161 The focus reduction neutralization test (FRNT) assay for measuring SARS-CoV-2 neutralizing  
162 antibodies was adapted from [40]. Confluent Vero E6-TMPRSS2-T2A-ACE2 cells (NR-54970, BEI  
163 Resources) were utilized to characterize initial and evolved SARS-CoV-2 viruses against six sera  
164 pools created based on anti-spike IgG levels (BAU/ml) (V-PLEX SARS-CoV-2 Panel 2 Kit, Meso  
165 Scale Diagnostics, LLC).

166

### 167 ***Statistical Analysis***

168 We summarized participant characteristics using proportions (frequencies), means (with  
169 standard deviations), and medians (with interquartile ranges). Comparisons of demographic  
170 characteristics and COVID-19 vaccination status were performed using Chi-square or  
171 Wilcoxon/Kruskal-Wallis tests when appropriate. The alpha level was not adjusted for multiple  
172 comparisons, except where indicated.

173

174 We compared the duration of rRT-PCR positivity (the number of days from day zero to last  
175 SARS-CoV-2 positive test date) among different immunocompromised groups using a Cox  
176 proportional hazards model with the autoimmune/autoinflammatory group as the referent (as  
177 this group had the lowest level of immunosuppression). Covariates included age, sex,  
178 race/ethnicity, prior COVID vaccination, and antiviral use at baseline (defined as receipt of any

179 antiviral between 90 days prior and 7 days after enrollment). Right censoring was applied for  
180 individuals who continued to test positive by rRT-PCR at 90 days. We used the log-rank test to  
181 compare differences among immunocompromising groups with  $p < 0.05$  considered statistically  
182 significant.

183

184 All analyses were conducted using R v4.1.3 (Boston, Massachusetts).

185

### 186 ***Data Availability***

187 Raw sequencing reads are available on the NCBI short read archive under BioProject

188 PRJNA896930 and consensus sequences are available on GISAID.

189

## 190 **RESULTS**

### 191 ***Participants***

192 During April 11, 2022 - October 1, 2022, 156 patients began enrollment procedures; 6 were  
193 excluded due to not completing enrollment procedures (3), not meeting eligibility criteria (2), or  
194 patient withdrawal (1), resulting in 150 patients in the final analysis (Supplementary Figure 1).

195 Patient follow-up continued until February 1, 2023. Among the 150 patients, 59 (39%) were  
196 male, and the median age was 60 years (Table 1). COVID-19 vaccination status at enrollment  
197 included 12 (8%) unvaccinated, 4 (3%) who had received one vaccine dose, and 134 (89%) who  
198 had received at least 2 vaccine doses. Immunocompromised category included 18 (12%) in the  
199 B cell dysfunction group, 59 (39%) in the SOT/HSCT group, 5 (3%) in the AIDS group, 23 (15%) in  
200 the malignancy group, and 45 (30%) in the autoimmune/autoinflammatory group (Table 1,

201 Supplemental Table 2). One hundred thirty-five (90%) were symptomatic at the time of  
202 enrollment. Median time from illness onset or initial positive SARS-CoV2 test to study  
203 enrollment was 5 days (IQR 3-11). One hundred eleven (74%) patients received antiviral  
204 treatment between 90 days prior to and 7 days after enrollment, including remdesivir,  
205 molnupiravir, nirmatrelvir/ritonavir, convalescent plasma, or any monoclonal antibody; 6 (4%)  
206 received tixagevimab/cilgavimab prophylaxis, 27 (18%) received bebtelovimab, 1 (0.7%)  
207 received sotrovimab, and 4 (2%) received convalescent plasma (Supplemental Table 2).

208  
209 All 150 patients were enrolled during the period of SARS-CoV-2 Omicron variant predominance.  
210 A lineage was determined for 102/150 (68%) patients, including 4/150 (3%) with BA.1, 46/150  
211 (31%) with BA.2, 9/150 (6%) with BA.4, 43/150 (29%) with BA.5, and lineage was unknown for  
212 48/150 (32%).

213

#### 214 ***Nucleic acid and culture positivity over time***

215 All 150 patients were enrolled based on a positive SARS-CoV-2 rRT-PCR test obtained in the  
216 clinical setting. Specimens from the enrollment visit tested positive by rRT-PCR for SARS-CoV-2  
217 at the central laboratory for 121/150 (81%) patients. Of these, the enrollment visit was the last  
218 positive SARS-CoV-2 rRT-PCR test at the central laboratory for 80/121 (66%) patients and only  
219 41/121 (34%) patients had at least one follow-up visit. This included 28 patients with a positive  
220 test at 1 follow-up visit, 7 patients with a positive test at 2 follow-up visits, and 6 patients with a  
221 positive test at  $\geq 3$  follow-up visits.

222

223 The individual trajectories of total viral RNA (as estimated from rRT-PCR Ct value) and the time  
224 to last positive test varied significantly across immunosuppressed groups (Figure 1). The median  
225 time to last positive rRT-PCR test overall was 9 days (IQR 2-26); the AIDS group had the longest  
226 median time to last positive rRT-PCR test (32 days, IQR 20-33), followed by the SOT/HSCT group  
227 (16 days, IQR 4-29) and B cell dysfunction group (11 days, IQR 3-44). The  
228 autoimmune/autoinflammatory group had the shortest time to last positive test at 4 days (IQR  
229 0-9). Compared to the autoimmune/autoinflammatory group, patients in the B cell dysfunction  
230 group (aHR 0.32, 95% CI 0.15-0.64), SOT/HSCT group (aHR 0.60, 95% CI 0.38-0.94), and AIDS  
231 group (aHR 0.28, 95% CI 0.08-1.00) had longer duration of infection, defined as time to last  
232 positive rRT-PCR test. No other covariates, including age, sex, ethnicity, vaccination status, or  
233 baseline antiviral use were associated with duration of infection (Supplemental Table 3).

234

235 Ct values for subgenomic viral RNA, a marker of active viral replication [32,41], tracked with  
236 total viral RNA Ct values across patients and timepoints (Supplemental Figure 2). Of the 192  
237 specimens positive for SARS-CoV-2 by rRT-PCR, 93 (48%) yielded positive viral culture. A  
238 positive culture for SARS-CoV-2 was achieved in 65% of specimens with a total viral RNA Ct  $\leq$ 32  
239 and 4% with Ct >32. Thirty-eight (25%) patients were positive for SARS-CoV-2 by rRT-PCR  $\geq$ 21  
240 days; of these, 16 (11%) patients had  $\geq$ 2 sequenced specimens with Ct  $\leq$ 32 over  $\geq$ 21 days  
241 (Supplemental Figure 3). Of these, 5 exhibited very prolonged replication for >56 days, including  
242 one patient with SARS-CoV-2 positivity by rRT-PCR for 207 days and by culture for 198 days, a  
243 second patient with SARS-CoV-2 positivity by rRT-PCR for 82 days and by culture for 82 days, a  
244 third patient with SARS-CoV-2 positivity by rRT-PCR for 157 days and by culture for 32 days, a

245 fourth patient with SARS-CoV-2 positivity by rRT-PCR for 75 days and by culture for 30 days, and  
246 a fifth patient with SARS-CoV-2 positivity by rRT-PCR for 203 days and by culture for 49 days  
247 (Supplemental Table 2).

248

### 249 ***Evolutionary divergence in persistent infection***

250 We obtained high depth of coverage sequence data suitable for identifying the whole genome  
251 consensus and iSNV from 149 (78%) specimens from 104 patients (Supplemental Figure 4). To  
252 account for the large number of fixed Omicron-defining mutations present in these samples,  
253 any mutation present at  $\geq 98\%$  frequency in the first sample for each patient was considered an  
254 Omicron-related mutation and was not examined further (see Methods). Using this definition,  
255 93 patients had *de novo* mutations or iSNV, and 65 of these had *de novo* non-synonymous  
256 mutations. There was no relationship between the number of iSNV identified and total viral  
257 RNA Ct value (Supplemental Figure 5). At each time point we identified similar numbers of iSNV,  
258 consistent with the dynamic gain and loss of both nonsynonymous and synonymous mutations  
259 (Figure 2A). We found evidence for significant divergence in multiple genes, including ORF1a,  
260 ORF1b, and spike (Supplemental Table 4). At a genome level, patients with persistent infection  
261 lasting  $\geq 21$  days ( $n=16$ ), compared to patients with short-term infection  $< 21$  days ( $n=72$ ), had an  
262 increased nonsynonymous divergence rate ( $2.73 \times 10^{-6}$  vs.  $5.75 \times 10^{-7}$  per site per day, Mann  
263 Whitney U test  $p=0.03$ ) and similar synonymous divergence rate (Mann Whitney U test  $p=0.29$ ).  
264 The overall mutation rate (including both non-synonymous and synonymous mutations) was  
265 similar between patients with short-term and persistent infection ( $5.80 \times 10^{-6}$  and  $3.95 \times 10^{-6}$ ,  
266 respectively; Mann Whitney U test  $p=0.16$ ) (Figure 2B).



267

268 ***Shared and within-host mutational evolution***

269 We examined if any newly arising mutations were shared among multiple patients, which  
270 would provide evidence for positive selection [42–44]. There were very few shared mutations in  
271 the study population (Figure 3A). The K444N substitution, in the receptor binding domain of  
272 Spike, was shared by 9 patients. This mutation has been associated with monoclonal antibody  
273 resistance, and 8 patients with this mutation received monoclonals [45,46]. The T1542I and  
274 T4311I substitutions, both in ORF1a and each shared by 4 patients (eventually achieving  
275 dominance in one patient), have not previously been reported in the literature and peaked at  
276 <1% frequency in the global population [47,48]. Five patients had new insertions or deletions at  
277 consensus level, most of which were not shared among multiple patients. Four deletions were  
278 shared by two patients each, all in the spike N-terminal domain: L141, G142, V143, and Y144.

279

280 Of the 5 patients with very prolonged viral shedding, 4 accumulated consensus level mutations  
281 in spike, 61% of which were in the receptor binding domain (RBD, Figure 3C, Supplemental  
282 Table 5). As in the entire patient population, there were few shared mutations. The K444N,  
283 G446D/R, and N450D substitutions were the only mutations shared by multiple patients; all are  
284 associated with monoclonal antibody resistance, but only two of the five patients received a  
285 monoclonal antibody. None of these mutations have been prevalent globally; K444N peaked at  
286 2% global frequency, and N450D at 3% global frequency, both in November 2022.

287

288 Of 23 consensus spike mutations identified in these five individuals, most have been seen in  
289 subsequent Omicron lineages. The 5 mutations (F157L, R346T, L368I, S371F, and T376A) that  
290 subsequently achieved >10% frequency globally were seen only in individual patients and not  
291 shared. The R346T substitution in one patient, which was not characteristic of the infecting  
292 BA.2.12.1 lineage, was subsequently a defining mutation in XBB and BQ.1.1 lineages. The L368I  
293 and 371F substitutions, which were not characteristic of the infecting BA.1.1 lineage, were seen  
294 in later Omicron lineages (371F) and XBB (L368I) lineages. Both were present at >60% frequency  
295 in the patient's first sample (day 13 of infection), making them less remarkable as markers of  
296 within-host evolution fostered by persistent infection. Notably, mutations at K356, V445, G446,  
297 and N450 — all identified in these patients but not frequently in the general population — are  
298 mutated in the recently identified and highly divergent BA.2.86 variant under monitoring.

299  
300 Neutralization assays with pooled sera against the initial and evolved viruses from patients with  
301 prolonged infection indicated that the evolved virus from patient EV138 (de novo spike  
302 mutations K444N, G446R) was antigenically distinct (mean  $\pm$  sd FRNT50 fold change  $-3.26 \pm$   
303  $1.02$ , vs. matched initial virus,  $n=6$  serum pools, Supplemental Table 6) while the evolved virus  
304 from patient EV022 (de novo spike mutations K444N, L452M) was not (FRNT50  $-0.25 \pm 1.09$   
305 fold change vs. matched initial virus).

306

### 307 ***Impact of antiviral treatment***

308 We examined mutational patterns in patients with pre-treatment and at least one post-  
309 treatment sequenced sample to determine if any resistance mutations developed in our study

310 population. A total of 115 (77%) patients received one or more antiviral treatments (including  
311 remdesivir, molnupiravir, nirmatrelvir/ritonavir, convalescent plasma, or any monoclonal  
312 antibody) at any time during the study period. Of the 42 patients who received a monoclonal  
313 antibody (including bebtelovimab, sotrovimab, and/or tixagevimab/cilgavimab), 16 (38%) had a  
314 post-treatment sample; of these, 10 (62%) had *de novo* (i.e., new in patient) nonsynonymous  
315 mutations in spike (Figure 4A, Table 2). There were several shared mutations among these  
316 patients, most of which were between positions 444-446 and have been associated with  
317 monoclonal antibody resistance [45,46].

318  
319 Among patients treated with antiviral drugs, 17 of 68 (25%) remdesivir-treated patients had at  
320 least one post-treatment sample; 7/17 (41%) had *de novo* mutations in nsp12, the target of  
321 remdesivir. Most of these mutations were present at very low frequency and were not shared  
322 among multiple patients; only one, M794I, was shared by 2 patients (Table 2, Figure 4B). While  
323 most have not been specifically associated with remdesivir resistance, three of these newly  
324 arising mutations have been associated with resistance, and several others are in close  
325 proximity to C799, where remdesivir resistance-associated substitutions have been identified  
326 [45,49]. Only one of the resistance-associated mutations, V792I, was present at high frequency  
327 in a single patient [6]. Five out of 20 (25%) nirmatrelvir/ritonavir-treated patients had a post-  
328 treatment sample, none of which had any mutations in nsp5 (Mpro) [45,50]. Five patients  
329 received molnupiravir, and 4 had a post-treatment sample. All four had a high number of  
330 nucleotide substitutions (ranging from 97 to >500), most of which were present at low

331 frequency and distributed evenly across the genome; most of these specimens were viral  
332 culture negative.

333  
334 Most patients who received antiviral treatments cleared their infections. Four who received any  
335 treatment (1 who received nirmatrelvir/ritonavir, 1 who received molnupiravir, 1 who received  
336 bebtelovimab, and 1 who received both bebtelovimab and remdesivir), went on to have very  
337 prolonged viral shedding >56 days (Supplemental Figure 6).

338

### 339 **DISCUSSION**

340 In this prospective, multicenter analysis conducted during the Omicron period, prolonged  
341 replication-competent SARS-CoV-2 infection among a diverse group of patients with moderate  
342 to severe immunocompromise was uncommon. Additionally, while numerous case reports of  
343 SARS-CoV-2 infection in immunocompromised hosts have documented significant mutation  
344 accumulation in spike that mirrors mutational profiles in VOC, our analysis demonstrated  
345 comparatively restricted SARS-CoV-2 evolution over a wide spectrum of immunocompromising  
346 conditions. We found that the within-host rate of evolution in immunocompromised hosts –  
347 captured as divergence – was similar in short-term and long-term infection. Our data suggest  
348 that the main difference in some immunocompromised hosts is the length of the infectious  
349 period, which allows for mutation accumulation without the constraint of transmission. In the  
350 few individuals with prolonged infection, we found accumulation of mutations within the RBD;  
351 the most prominent alterations have rarely, if ever, been detected in subsequent SARS-CoV-2

352 sequences in global databases. We did find several substitutions also present in concurrent or  
353 subsequent Omicron lineages.

354  
355 Our analysis identified B cell dysfunction/depletion due to lymphoma or myeloma, or anti-  
356 CD20/anti-CD19 therapy, as a strong risk factor for longer duration of SARS-CoV-2 infection  
357 among the immunocompromised population (see also [51]). This is consistent with published  
358 case reports, where nearly all of those with infections lasting >150 days had B cell malignancy  
359 with receipt of anti-CD20 antibodies or CAR-T cells [7,9,15–18,52–65]. Although we enrolled 59  
360 SOT and HSCT patients with ongoing T cell immunosuppression – due to tacrolimus,  
361 prednisone, and/or mycophenolate – only one had infection lasting >56 days. These findings  
362 highlight the importance of antibodies in SARS-CoV-2 clearance, both consistent with what has  
363 been seen in other viruses, and with emerging evidence of antibodies as correlates of  
364 protection in SARS-CoV-2 [66–70]. One of our cases with very prolonged infection (>200 days)  
365 was in a person living with AIDS with a CD4 T cell count <50 and uncontrolled HIV replication.  
366 This is consistent with both case reports [17] and a systematic review [71], which found that  
367 prolonged replication in people living with HIV is seen at extremely low CD4 counts (<50) and  
368 high HIV viral loads. This may also reflect impaired humoral immunity, as B cell responses are  
369 compromised in advanced AIDS [72].

370  
371 Because we collected specimens at regular intervals for rRT-PCR and viral culture, we were able  
372 to examine the kinetics of viral clearance in patients who received antiviral therapy. Among 115  
373 individuals treated with antivirals, only four did not clear their infection. In the four failures,

374 both patients who received bebtelovimab developed associated resistance mutations. A third  
375 patient received remdesivir and developed a mutation associated with remdesivir resistance,  
376 V792I. While our data suggest that most immunocompromised patients have good virological  
377 responses to antiviral treatment, there is a need for further studies of extended treatment  
378 courses or combination therapy in those at highest risk for prolonged infection [73,74].

379  
380 The observed viral evolutionary dynamics in our surveillance cohort may differ from what was  
381 reported earlier in the pandemic. Many published cases of prolonged SARS-CoV-2 infection  
382 were in patients who had received convalescent plasma or early generation monoclonal  
383 antibodies (e.g., bamlanivimab), both of which tend to select for the same escape mutations  
384 (e.g., N-terminal domain mutations, E484K, and others) as infection- or vaccine-induced  
385 antibodies. In immunocompromised hosts treated with therapeutic antibodies, SARS-CoV-2 is  
386 likely to encounter intensified selective pressures similar to those at the global scale. In the  
387 absence of treatment, however, many immunocompromised hosts will have little antibody  
388 pressure on the spike protein, and the within-host and current global selective pressures may  
389 not align. People living with AIDS may differ from those with B cell dysfunction or depletion, as  
390 the former might plausibly mount an attenuated antibody response sufficient to select for  
391 mutations in the absence of viral eradication. While the origin of the highly divergent BA.2.86  
392 variant is unclear, mutations in this variant at positions 445 and 446 were identified in 2/3  
393 patients and 3/5 patients, respectively, who received monoclonal antibodies. Our serological  
394 data suggest that K444N and G446R together lead to increased neutralizing antibody escape.

395

396 Our study is subject to limitations. First, although we included 150 immunocompromised  
397 patients with SARS-CoV-2 infection in this longitudinal evaluation, only 41 (27%) had a follow-  
398 up specimen that tested positive by rRT-PCR, limiting the number of individuals in whom  
399 relevant features of viral evolution emerging on the population level could be assessed. Second,  
400 the definition of immunocompromise in the study was intentionally broad to capture as many  
401 patients as possible who might be at risk for prolonged infection and avoid bias toward any  
402 particular group. However, this breadth likely also led to the inclusion of patients with modest  
403 immune impairment who were less likely to experience prolonged infection and virus evolution.  
404 Third, the frequency of specimen collection at 2–4 week intervals was optimal to assess interval  
405 change in mutations among patients with prolonged infection, but too infrequent to determine  
406 precise estimates of the duration of rRT-PCR-positivity, as 73% did not have a positive specimen  
407 after enrollment. Fourth, we did not enroll immunocompetent patients who could have  
408 provided a referent group to compare duration of rRT-PCR-positivity by type of  
409 immunosuppression. Prior studies showing that prolonged positivity in immunocompetent  
410 adults is rare contributed to our decision not to include an immunocompetent comparator  
411 group [41]. Finally, our results from a US-based population may not generalize to  
412 immunocompromised hosts in other settings. Recipients of SOT, HSCT, CAR-T, and/or anti-CD20  
413 monoclonal antibodies were over-represented in our study and people living with AIDS were  
414 under-represented. Findings may differ in locations where AIDS is more prevalent and access to  
415 SARS-CoV-2 antivirals and COVID-19 vaccines is lower [17].  
416

417 In conclusion, in this prospective cohort of immunocompromised adults with SARS-CoV-2  
418 infection, duration of infection and evolution of SARS-CoV-2 were observed more frequently in  
419 patients with B cell malignancy and B cell depletion. With extended viral replication, these  
420 immunocompromised individuals can accumulate significant numbers of mutations in the spike  
421 protein and elsewhere across the genome and exhibit marginally accelerated viral evolution. In  
422 our cohort of individuals infected with Omicron variant SARS-CoV-2, mutations arising within  
423 immunocompromised hosts were only weakly predictive of subsequent Omicron mutations at a  
424 population scale, suggesting that alternative genomic surveillance approaches may be more  
425 useful [75]

426

#### 427 **ACKNOWLEDGEMENTS**

428 We thank all participants in this study and all contributors to the Global Initiative on Sharing All  
429 Influenza Data (GISAID) sequence database.

430

#### 431 **FUNDING ACKNOWLEDGEMENT**

432 Primary funding for this study was provided by the US Centers for Disease Control and  
433 Prevention (CDC) (award 75D30121F00002). Scientists from the US CDC participated in all  
434 aspects of this study, including its design, analysis, interpretation of data, writing the report,  
435 and the decision to submit the article for publication.

436 ZR was supported by NIH T32HL007749.

437

#### 438 **DISCLAIMER**



439 The findings and conclusions in this report are those of the authors and do not necessarily  
440 represent the official position of the Centers for Disease Control and Prevention (CDC).

441

#### 442 **CONFLICTS OF INTEREST**

443 All authors have completed ICMJE disclosure forms ([www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf)). James  
444 Chappell reports receiving grants from NIH and DoD, outside the submitted work. Carlos  
445 Grijalva reports grants from NIH, CDC, AHRQ, FDA, Campbell Alliance/Syneos Health, consulting  
446 fees and participating on a DSMB for Merck, outside the submitted work. Anne Frosch reports a  
447 K08 award from NIH and participating on the Hennepin Health Research Institute Board of  
448 Directors, outside the submitted work. Natasha Halasa reports grants from Sanofi, Quidel, and  
449 Merck, outside the submitted work. Adam Lauring reports receiving grants from CDC, NIAID,  
450 Burroughs Wellcome Fund, Flu Lab, and consulting fees from Roche, outside the submitted  
451 work. Emily Martin reports receiving a grant from Merck, outside the submitted work.

452

#### 453 **REFERENCES**

- 454 1 Lauring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2—What Do They Mean? *JAMA*  
455 2021;**325**:529. doi:10.1001/jama.2020.27124
- 456 2 Tao K, Tzou PL, Nouhin J, *et al.* The biological and clinical significance of emerging SARS-CoV-  
457 2 variants. *Nat Rev Genet* Published Online First: 17 September 2021. doi:10.1038/s41576-  
458 021-00408-x
- 459 3 Kwon JH, Tenforde MW, Gaglani M, *et al.* mRNA Vaccine Effectiveness Against Coronavirus  
460 Disease 2019 Hospitalization Among Solid Organ Transplant Recipients. *The Journal of*  
461 *Infectious Diseases* 2022;**226**:797–807. doi:10.1093/infdis/jiac118
- 462 4 Tenforde MW, Self WH, Adams K, *et al.* Association Between mRNA Vaccination and COVID-  
463 19 Hospitalization and Disease Severity. *JAMA* Published Online First: 4 November 2021.  
464 doi:10.1001/jama.2021.19499

- 465 5 Gliga S, Lübke N, Killer A, *et al.* Rapid Selection of Sotrovimab Escape Variants in Severe  
466 Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised  
467 Patients. *Clinical Infectious Diseases* 2023;**76**:408–15. doi:10.1093/cid/ciac802
- 468 6 Hogan JI, Duerr R, Dimartino D, *et al.* Remdesivir Resistance in Transplant Recipients With  
469 Persistent Coronavirus Disease 2019. *Clinical Infectious Diseases* 2023;**76**:342–5.  
470 doi:10.1093/cid/ciac769
- 471 7 Baang JH, Smith C, Mirabelli C, *et al.* Prolonged Severe Acute Respiratory Syndrome  
472 Coronavirus 2 Replication in an Immunocompromised Patient. *The Journal of Infectious*  
473 *Diseases* 2021;**223**:23–7. doi:10.1093/infdis/jiaa666
- 474 8 Avanzato VA, Matson MJ, Seifert SN, *et al.* Case Study: Prolonged Infectious SARS-CoV-2  
475 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell*  
476 2020;**183**:1901-1912.e9. doi:10.1016/j.cell.2020.10.049
- 477 9 Choi B, Choudhary MC, Regan J, *et al.* Persistence and Evolution of SARS-CoV-2 in an  
478 Immunocompromised Host. *N Engl J Med* 2020;**383**:2291–3. doi:10.1056/NEJMc2031364
- 479 10 Aydililo T, Gonzalez-Reiche AS, Aslam S, *et al.* Shedding of Viable SARS-CoV-2 after  
480 Immunosuppressive Therapy for Cancer. *N Engl J Med* 2020;**383**:2586–8.  
481 doi:10.1056/NEJMc2031670
- 482 11 Caillard S, Benotmane I, Gautier Vargas G, *et al.* SARS-CoV-2 viral dynamics in  
483 immunocompromised patients. *American Journal of Transplantation* 2021;**21**:1667–9.  
484 doi:10.1111/ajt.16353
- 485 12 Roedl K, Heidenreich S, Pfefferle S, *et al.* Viral Dynamics of SARS-CoV-2 in Critically Ill  
486 Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients  
487 with COVID-19. *Am J Respir Crit Care Med* 2021;**203**:242–5. doi:10.1164/rccm.202009-  
488 3386LE
- 489 13 Meiring S, Tempia S, Bhiman JN, *et al.* Prolonged Shedding of Severe acute respiratory  
490 syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized  
491 Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South  
492 Africa. *Clinical Infectious Diseases* 2022;:ciac077. doi:10.1093/cid/ciac077
- 493 14 Cohen C, Kleynhans J, von Gottberg A, *et al.* SARS-CoV-2 incidence, transmission, and  
494 reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa,  
495 2020–21. *The Lancet Infectious Diseases* 2022;**22**:821–34. doi:10.1016/S1473-  
496 3099(22)00069-X
- 497 15 Chaguza C, Hahn AM, Petrone ME, *et al.* Accelerated SARS-CoV-2 intrahost evolution  
498 leading to distinct genotypes during chronic infection. *Cell Reports Medicine* 2023;:100943.  
499 doi:10.1016/j.xcrm.2023.100943

- 500 16 Nussenblatt V, Roder AE, Das S, *et al.* Yearlong COVID-19 Infection Reveals Within-Host  
501 Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion. *The Journal of Infectious Diseases*  
502 2022;**225**:1118–23. doi:10.1093/infdis/jiab622
- 503 17 Cele S, Karim F, Lustig G, *et al.* SARS-CoV-2 prolonged infection during advanced HIV  
504 disease evolves extensive immune escape. *Cell Host & Microbe* 2022;**30**:154-162.e5.  
505 doi:10.1016/j.chom.2022.01.005
- 506 18 Scherer EM, Babiker A, Adelman MW, *et al.* SARS-CoV-2 Evolution and Immune Escape  
507 in Immunocompromised Patients. *N Engl J Med* 2022;:NEJMc2202861.  
508 doi:10.1056/NEJMc2202861
- 509 19 Harari S, Tahor M, Rutsinsky N, *et al.* Drivers of adaptive evolution during chronic SARS-  
510 CoV-2 infections. *Nat Med* Published Online First: 20 June 2022. doi:10.1038/s41591-022-  
511 01882-4
- 512 20 Wilkinson SAJ, Richter A, Casey A, *et al.* Recurrent SARS-CoV-2 mutations in  
513 immunodeficient patients. *Virus Evolution* 2022;**8**:veac050. doi:10.1093/ve/veac050
- 514 21 Braun KM, Moreno GK, Wagner C, *et al.* Acute SARS-CoV-2 infections harbor limited  
515 within-host diversity and transmit via tight transmission bottlenecks. *PLoS Pathog*  
516 2021;**17**:e1009849. doi:10.1371/journal.ppat.1009849
- 517 22 Martin MA, Koelle K. Reanalysis of deep-sequencing data from Austria points towards a  
518 small SARS-COV-2 transmission bottleneck on the order of one to three virions. *Evolutionary*  
519 *Biology* 2021. doi:10.1101/2021.02.22.432096
- 520 23 Bendall EE, Callear AP, Getz A, *et al.* Rapid transmission and tight bottlenecks constrain  
521 the evolution of highly transmissible SARS-CoV-2 variants. *Nat Commun* 2023;**14**:272.  
522 doi:10.1038/s41467-023-36001-5
- 523 24 Gonzalez-Reiche AS, Alshammary H, Schaefer S, *et al.* Intrahost evolution and forward  
524 transmission of a novel SARS-CoV-2 Omicron BA.1 subvariant. *Infectious Diseases (except*  
525 *HIV/AIDS)* 2022. doi:10.1101/2022.05.25.22275533
- 526 25 Choudhary MC, Crain CR, Qiu X, *et al.* Severe Acute Respiratory Syndrome Coronavirus 2  
527 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence  
528 and Reinfection. *Clinical Infectious Diseases* 2022;**74**:237–45. doi:10.1093/cid/ciab380
- 529 26 Kemp SA, Collier DA, Datir RP, *et al.* SARS-CoV-2 evolution during treatment of chronic  
530 infection. *Nature* 2021;**592**:277–82. doi:10.1038/s41586-021-03291-y
- 531 27 Hill V, Du Plessis L, Peacock TP, *et al.* The origins and molecular evolution of SARS-CoV-2  
532 lineage B.1.1.7 in the UK. *Virus Evolution* 2022;**8**:veac080. doi:10.1093/ve/veac080

- 533 28 Corey L, Beyrer C, Cohen MS, *et al.* SARS-CoV-2 Variants in Patients with  
534 Immunosuppression. *The new england journal of medicine* 2021;:5.
- 535 29 Lauring AS, Tenforde MW, Chappell JD, *et al.* Clinical severity of, and effectiveness of  
536 mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the  
537 United States: prospective observational study. *BMJ* 2022;**376**:e069761. doi:10.1136/bmj-  
538 2021-069761
- 539 30 Barnes E, Goodyear CS, Willicombe M, *et al.* SARS-CoV-2-specific immune responses and  
540 clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.  
541 *Nat Med* 2023;**29**:1760–74. doi:10.1038/s41591-023-02414-4
- 542 31 Lu X, Wang L, Sakthivel SK, *et al.* US CDC Real-Time Reverse Transcription PCR Panel for  
543 Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*  
544 2020;**26**:1654–65. doi:10.3201/eid2608.201246
- 545 32 Dimcheff DE, Valesano AL, Rumfelt KE, *et al.* Severe Acute Respiratory Syndrome  
546 Coronavirus 2 Total and Subgenomic RNA Viral Load in Hospitalized Patients. *The Journal of*  
547 *Infectious Diseases* 2021;**224**:1287–93. doi:10.1093/infdis/jiab215
- 548 33 Harcourt J, Tamin A, Lu X, *et al.* Severe Acute Respiratory Syndrome Coronavirus 2 from  
549 Patient with Coronavirus Disease, United States - Volume 26, Number 6—June 2020 -  
550 Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2606.200516
- 551 34 Quick J. nCoV2-2019 sequencing protocol v3 (LoCost) V.3.  
552 <https://www.protocols.io/view/ncov-2019-sequencing-protocol-%20v3-locost-bh42j8ye>  
553 (accessed 26 May 2021).
- 554 35 Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.  
555 *Bioinformatics* 2009;**25**:1754–60. doi:10.1093/bioinformatics/btp324
- 556 36 Grubaugh ND, Gangavarapu K, Quick J, *et al.* An amplicon-based sequencing framework  
557 for accurately measuring intrahost virus diversity using PrimalSeq and iVar. *Genome Biol*  
558 2019;**20**:8. doi:10.1186/s13059-018-1618-7
- 559 37 Aksamentov I, Roemer C, Hodcroft EB, *et al.* Nextclade: clade assignment, mutation  
560 calling and quality control for viral genomes. *Journal of Open Source Software* 2021;**6**:3773.  
561 doi:10.21105/joss.03773
- 562 38 De Maio N, Walker C, Borges R, *et al.* Issues with SARS-CoV-2 sequencing data.  
563 *Virological* Published Online First: 14 May 2020.<https://virological.org/t/issues-with-sars-cov-2-sequencing-data/473> (accessed 6 Oct 2022).
- 565 39 Xue KS, Bloom JD. Linking influenza virus evolution within and between human hosts.  
566 *Virus Evolution* 2020;**6**:veaa010. doi:10.1093/ve/veaa010

- 567 40 Vanderheiden A, Edara VV, Floyd K, *et al.* Development of a Rapid Focus Reduction  
568 Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. *Curr Protoc*  
569 *Immunol* 2020;**131**:e116. doi:10.1002/cpim.116
- 570 41 Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. *Nat Rev*  
571 *Microbiol* 2023;**21**:147–61. doi:10.1038/s41579-022-00822-w
- 572 42 Moncla LH, Bedford T, Dussart P, *et al.* Quantifying within-host diversity of H5N1  
573 influenza viruses in humans and poultry in Cambodia. *PLoS Pathog* 2020;**16**:e1008191.  
574 doi:10.1371/journal.ppat.1008191
- 575 43 Xue KS, Stevens-Ayers T, Campbell AP, *et al.* Parallel evolution of influenza across  
576 multiple spatiotemporal scales. *eLife* 2017;**6**:e26875. doi:10.7554/eLife.26875
- 577 44 Valesano AL, Taniuchi M, Fitzsimmons WJ, *et al.* The Early Evolution of Oral Poliovirus  
578 Vaccine Is Shaped by Strong Positive Selection and Tight Transmission Bottlenecks. *Cell Host*  
579 *& Microbe* 2020;:S1931312820305746. doi:10.1016/j.chom.2020.10.011
- 580 45 Tzou PL, Tao K, Pond SLK, *et al.* Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2  
581 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated  
582 persons. *PLoS One* 2022;**17**:e0261045. doi:10.1371/journal.pone.0261045
- 583 46 Westendorf K, Žentelis S, Wang L, *et al.* LY-CoV1404 (bebtelovimab) potently neutralizes  
584 SARS-CoV-2 variants. *Cell Reports* 2022;**39**:110812. doi:10.1016/j.celrep.2022.110812
- 585 47 Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to  
586 reality. *Euro Surveill* 2017;**22**:30494. doi:10.2807/1560-7917.ES.2017.22.13.30494
- 587 48 Gangavarapu K, Latif AA, Mullen JL, *et al.* Outbreak.info genomic reports: scalable and  
588 dynamic surveillance of SARS-CoV-2 variants and mutations. *Nat Methods* 2023;:1–11.  
589 doi:10.1038/s41592-023-01769-3
- 590 49 Stevens LJ, Pruijssers AJ, Lee HW, *et al.* Mutations in the SARS-CoV-2 RNA-dependent  
591 RNA polymerase confer resistance to remdesivir by distinct mechanisms. *Sci Transl Med*  
592 2022;**14**:eabo0718. doi:10.1126/scitranslmed.abo0718
- 593 50 Zhou Y, Gammeltoft KA, Ryberg LA, *et al.* Nirmatrelvir-resistant SARS-CoV-2 variants  
594 with high fitness in an infectious cell culture system. *Sci Adv*;8:eadd7197.  
595 doi:10.1126/sciadv.add7197
- 596 51 Li Y, Choudhary MC, Regan J, *et al.* SARS-CoV-2 Viral Clearance and Evolution Varies by  
597 Extent of Immunodeficiency. 2023;:2023.07.31.23293441.  
598 doi:10.1101/2023.07.31.23293441

- 599 52 Burel E, Colson P, Lagier J-C, *et al.* Sequential Appearance and Isolation of a SARS-CoV-2  
600 Recombinant between Two Major SARS-CoV-2 Variants in a Chronically Infected  
601 Immunocompromised Patient. *Viruses* 2022;**14**:1266. doi:10.3390/v14061266
- 602 53 Bailly B, Péré H, Veyer D, *et al.* Persistent COVID-19 in an immunocompromised host  
603 treated by SARS-CoV-2-specific monoclonal antibodies. *Clinical Infectious Diseases*  
604 2021;:ciab868. doi:10.1093/cid/ciab868
- 605 54 Monrad I, Sahlertz SR, Nielsen SSF, *et al.* Persistent Severe Acute Respiratory Syndrome  
606 Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral  
607 Evolution. *Open Forum Infectious Diseases* 2021;**8**:ofab295. doi:10.1093/ofid/ofab295
- 608 55 Stanevich OV, Alekseeva EI, Sergeeva M, *et al.* SARS-CoV-2 escape from cytotoxic T cells  
609 during long-term COVID-19. *Nat Commun* 2023;**14**:149. doi:10.1038/s41467-022-34033-x
- 610 56 Hettle D, Hutchings S, Muir P, *et al.* Persistent SARS-CoV-2 infection in  
611 immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study  
612 and literature review. *Clinical Infection in Practice* 2022;**16**:100210.  
613 doi:10.1016/j.clinpr.2022.100210
- 614 57 Munnink BBO, Nijhuis RHT, Worp N, *et al.* Highly Divergent SARS-CoV-2 Alpha Variant in  
615 Chronically Infected Immunocompromised Person. *Emerg Infect Dis* 2022;**28**:1920–3.  
616 doi:10.3201/eid2809.220875
- 617 58 Truong TT, Ryutov A, Pandey U, *et al.* Increased viral variants in children and young  
618 adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive  
619 case series. *EBioMedicine* 2021;**67**:103355. doi:10.1016/j.ebiom.2021.103355
- 620 59 Fourati S, Gautier G, Chovelon M, *et al.* Persistent SARS-CoV-2 Alpha Variant Infection in  
621 Immunosuppressed Patient, France, February 2022. *Emerg Infect Dis* 2022;**28**:1512–5.  
622 doi:10.3201/eid2807.220467
- 623 60 Sonnleitner ST, Prelog M, Sonnleitner S, *et al.* Cumulative SARS-CoV-2 mutations and  
624 corresponding changes in immunity in an immunocompromised patient indicate viral  
625 evolution within the host. *Nat Commun* 2022;**13**:2560. doi:10.1038/s41467-022-30163-4
- 626 61 Caccuri F, Messali S, Bortolotti D, *et al.* Competition for dominance within replicating  
627 quasispecies during prolonged SARS-CoV-2 infection in an immunocompromised host. *Virus*  
628 *Evol* 2022;**8**:veac042. doi:10.1093/ve/veac042
- 629 62 Borges V, Isidro J, Cunha M, *et al.* Long-Term Evolution of SARS-CoV-2 in an  
630 Immunocompromised Patient with Non-Hodgkin Lymphoma. *mSphere* 2021;**6**:e00244-21.  
631 doi:10.1128/mSphere.00244-21

- 632 63 Van der Moeren N, Selhorst P, Ha M, *et al.* Viral Evolution and Immunology of SARS-  
633 CoV-2 in a Persistent Infection after Treatment with Rituximab. *Viruses* 2022;**14**:752.  
634 doi:10.3390/v14040752
- 635 64 Gandhi S, Klein J, Robertson AJ, *et al.* De novo emergence of a remdesivir resistance  
636 mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised  
637 patient: a case report. *Nat Commun* 2022;**13**:1547. doi:10.1038/s41467-022-29104-y
- 638 65 Weigang S, Fuchs J, Zimmer G, *et al.* Within-host evolution of SARS-CoV-2 in an  
639 immunosuppressed COVID-19 patient as a source of immune escape variants. *Nat Commun*  
640 2021;**12**:6405. doi:10.1038/s41467-021-26602-3
- 641 66 Bok K, Prevots DR, Binder AM, *et al.* Epidemiology of Norovirus Infection Among  
642 Immunocompromised Patients at a Tertiary Care Research Hospital, 2010–2013. *Open Forum*  
643 *Infectious Diseases* 2016;**3**:ofw169. doi:10.1093/ofid/ofw169
- 644 67 Lumby CK, Zhao L, Oporto M, *et al.* Favipiravir and Zanamivir Cleared Infection with  
645 Influenza B in a Severely Immunocompromised Child. *Clinical Infectious Diseases* 2020;:Mar  
646 3;ciaa023. doi: 10.1093/cid/ciaa023. Online ahead of print.
- 647 68 Dunn G, Klapsa D, Wilton T, *et al.* Twenty-Eight Years of Poliovirus Replication in an  
648 Immunodeficient Individual: Impact on the Global Polio Eradication Initiative. *PLoS Pathog*  
649 2015;**11**:e1005114. doi:10.1371/journal.ppat.1005114
- 650 69 DeVries AS, Harper J, Murray A, *et al.* Vaccine-Derived Poliomyelitis 12 Years after  
651 Infection in Minnesota. *N Engl J Med* 2011;**364**:2316–23. doi:10.1056/NEJMoa1008677
- 652 70 Regev-Yochay G, Lustig Y, Joseph G, *et al.* Correlates of protection against COVID-19  
653 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-  
654 CoV-2 in households in Israel (ICoFS): a prospective cohort study. *The Lancet Microbe*  
655 2023;**4**:e309–18. doi:10.1016/S2666-5247(23)00012-5
- 656 71 Peters JL, Fall A, Langerman SD, *et al.* Prolonged Severe Acute Respiratory Syndrome  
657 Coronavirus 2 Delta Variant Shedding in a Patient With AIDS: Case Report and Review of the  
658 Literature. *Open Forum Infectious Diseases* 2022;**9**:ofac479. doi:10.1093/ofid/ofac479
- 659 72 Moir S, Fauci AS. B-cell responses to HIV infection. *Immunological Reviews* 2017;**275**:33–  
660 48. doi:10.1111/imr.12502
- 661 73 Ford ES, Simmons W, Karmarkar EN, *et al.* Successful Treatment of Prolonged, Severe  
662 Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic  
663 Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir. *Clinical*  
664 *Infectious Diseases* 2023;**76**:926–9. doi:10.1093/cid/ciac868
- 665 74 Breeden M, Aitken SL, Baang JH, *et al.* Successful Treatment of Prolonged Severe Acute  
666 Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With

667 Extended Nirmatrelvir/Ritonavir: Case Series. *Open Forum Infect Dis* 2023;**10**:ofad189.  
668 doi:10.1093/ofid/ofad189

669 75 Harari S, Miller D, Fleishon S, *et al.* Using big sequencing data to identify chronic SARS-  
670 Coronavirus-2 infections. *Evolutionary Biology* 2023. doi:10.1101/2023.07.16.549184

671


672



673 **Table 1.** Characteristics at enrollment of immunocompromised patients with SARS-CoV-2  
 674 infection — IVY Network, 5 U.S. States\*, April 11, 2022 – February 1, 2023


Characteristic	All patients (N=150) n (%)	B cell dysfunction (N=18) n (%)	SOT/HSCT (N=59) n (%)	AIDS (N=5) n (%)	Malignancy (N=23) n (%)	Autoimmune/ Autoinflammatory (N=45) n (%)
Median age, yrs (IQR)	60 (46–68)	64 (50–71)	60 (46–68)	46 (45–57)	65 (53–70)	57 (46–65)
<b>Sex</b>						
Female	91 (61)	11 (61)	27 (46)	3 (60)	15 (65)	35 (78)
Male	59 (39)	7 (39)	32 (54)	2 (40)	8 (35)	10 (22)
<b>Race and ethnicity</b>						
White, non-Hispanic	88 (59)	8 (44)	33 (56)	1 (20)	17 (74)	29 (64)
Black, non-Hispanic	39 (26)	5 (28)	20 (34)	2 (40)	2 (9)	10 (22)
Hispanic	11 (7)	3 (17)	3 (5)	0 (0)	1 (4)	4 (9)
Other race, Unknown	12 (8)	2 (11)	3 (5)	2 (40)	3 (13)	2 (4)
<b>Presence of symptoms at enrollment</b>						
Asymptomatic	15 (10)	1 (6)	8 (14)	1 (20)	2 (9)	3 (7)
Symptomatic	135 (90)	17 (94)	51 (86)	4 (80)	21 (91)	42 (93)
<b>Days from illness onset or positive SARS-CoV-2 test result to enrollment</b>						
Median days (IQR)	5 (3–11)	5 (3–14)	5 (3–11)	2 (2–3)	4 (3–6)	5 (3–9)
<b>Number of COVID-19 vaccine doses received</b>						
0	12 (8)	2 (11)	2 (3)	1 (20)	3 (13)	4 (9)
1	4 (3)	0 (0)	3 (5)	0 (0)	0 (0)	1 (2)
2	26 (17)	1 (6)	13 (22)	1 (20)	2 (9)	9 (20)
3	63 (42)	11 (61)	17 (29)	1 (20)	15 (65)	19 (42)
4	37 (25)	4 (22)	19 (32)	2 (40)	2 (9)	10 (22)
5 or more	8 (5)	0 (0)	5 (9)	0 (0)	1 (4)	2 (4)
<b>COVID-19 Antiviral Drug Use at Baseline (Between 90 days prior to and 7 days after first visit)</b>						
No	39 (26)	3 (17)	11 (19)	2 (40)	4 (17)	19 (42)
Yes	111 (74)	15 (83)	48 (81)	3 (60)	19 (83)	26 (58)
88						
<b>Viral Lineage</b>						
BA.1	4 (3)	2 (11)	1 (2)	1 (20)	0 (0)	0 (0)
BA.2	46 (31)	9 (50)	19 (32)	1 (20)	8 (35)	9 (20)
BA.4	9 (6)	2 (11)	1 (2)	0 (0)	2 (9)	4 (9)
BA.5	43 (29)	2 (11)	17 (29)	2 (40)	8 (35)	14 (31)
Unknown	48 (32)	3 (17)	21 (36)	1 (20)	5 (22)	18 (40)
<b>Days to last SARS-CoV-2-positive RT-PCR test result</b>						
Median days (IQR)	9 (2-26)	11 (3-44)	16 (4-29)	32 (20-33)	9 (3-27)	4 (0-9)

675  
 676 **Abbreviations:** SARS-CoV-2 = severe acquired respiratory syndrome coronavirus 2; SOT/HSCT = solid organ  
 677 transplant/hematopoietic stem cell transplant; AIDS = acquired immunodeficiency syndrome; IQR = interquartile range; rRT-  
 678 PCR = real time reverse transcription polymerase chain reaction  
 679 \*Participants were enrolled from the following medical centers in 5 U.S. states: Michigan Medicine (Ann Arbor, MI), Vanderbilt  
 680 University Medical Center (Nashville, TN), Montefiore Medical Center (Bronx, NY), Hennepin County Medical Center  
 681 (Minneapolis, MN), and Washington University Medical Center (St. Louis, MO).  
 682 #First positive SARS-CoV-2 test was used for asymptomatic patients ^Includes any COVID-19 vaccine formulation




683

684 **Figure 1.** Temporal dynamics of SARS-CoV-2 RNA viral load and culture positivity in 121  
 685 immunocompromised patients with SARS-CoV-2 infection. (A) Cycle threshold (Ct) values for  
 686 total SARS-CoV-2 RNA and virus culture isolation over time in 121 patients by  
 687 immunocompromised group. Open and closed circles indicate culture negative and positive  
 688 specimens, respectively. (B) Kaplan-Meier survival curves showing time to last positive rRT-PCR  
 689 test by immunocompromised group.  $p = 0.003$  for difference in time to last positive specimen  
 690 across groups.




691  
692

693 **Figure 2.** Within-host evolution of SARS-CoV-2 in 104 immunocompromised patients. (A)  
694 Stacked columns show percent of newly arising mutations identified at >2% frequency for  
695 specimens collected during the indicated time periods with mutation types color-coded:  
696 nonsynonymous (teal), noncoding (purple), stop codon (blue), synonymous (pink). Number of  
697 samples in each group is listed atop each bar; n = 93. (B) Genome-wide within-host divergence  
698 rate for individuals positive for SARS-CoV-2 by rRT-PCR for <21 days (n = 72) compared to those  
699 positive for ≥21 days (n = 16). Individuals in each group with rates of zero (e.g., no mutations  
700 identified ≥2% frequency in the final specimen) are not plotted given log transformation of y-  
701 axis and are indicated in parentheses at bottom of plot; however, these were included in the  
702 statistical analysis. Mann Whitney U test p=0.03 for differences in nonsynonymous rates and  
703 p=0.29 for differences in synonymous rates between prolonged and self-limited infections.  
704 Points are color-coded by immunocompromised group: B cell dysfunction, purple; SOT or HSCT,  
705 teal; AIDS, blue; non-B cell malignancy, pink; autoimmune/autoinflammatory, orange.  
706



707  
 708 **Figure 3.** *De novo* non-synonymous SARS-CoV-2 mutations in 65 immunocompromised hosts.  
 709 (A) Mutations shared by the indicated number of individuals (y-axis), color coded by gene.  
 710 Amino acid substitutions are labeled if shared by  $\geq 5\%$  ( $n=4$ ) of patients. (B) Mutations in spike  
 711 shared by the indicated number of individuals (y-axis), color coded by domain. Amino acid  
 712 substitutions are labeled if shared by  $\geq 5\%$  ( $n=4$ ) of patients. (C) Heatmaps of *de novo*  
 713 nonsynonymous mutations in SARS-CoV-2 spike and their frequencies in five individuals with  
 714 infections lasting  $>56$  days and with  $\geq 2$  sequenced samples. Patients are color coded by  
 715 immunocompromised group: B cell dysfunction, purple; SOT or HSCT, teal; AIDS, blue; non-B  
 716 cell malignancy, pink; autoimmune/autoinflammatory, orange. Day of infection is indicated on  
 717 the Y axis. EV138 received bebtelovimab on day 1, and EV022 received bebtelovimab at day 68.  
 718 Mutations in the receptor binding domain are indicated by bold italics. Bisected squares  
 719 indicate more than one codon mutation identified produced the same amino acid substitution.  
 720 In EV022, shading at position 371 reflects the combined frequency of the 371F and 371P alleles.

721



722

723 **Figure 4.** Mutations in 15 patients who received antiviral treatment. (A) Heatmap of *de novo*  
 724 nonsynonymous mutations in SARS-CoV-2 spike among immunocompromised patients who  
 725 received monoclonal antibody (bebtelovimab, sotrovimab, and/or tixagevimab/cilgavimab) and  
 726 had a post-treatment sample that was sequenced (n=10). Sixteen patients had a post-treatment  
 727 monoclonal antibody sample; of these, 10 had *de novo* non-synonymous mutations in spike.  
 728 Patients are color coded by immunocompromised group: B cell dysfunction, purple; SOT or  
 729 HSCT, teal; AIDS, blue; non-B cell malignancy, pink; autoimmune/autoinflammatory, orange.  
 730 Monoclonal antibody received and treatment timepoints are denoted for each patient.  
 731 Mutations in the receptor binding domain are shown in bold italics. Bisected squares indicate  
 732 more than one codon mutation produced the same amino acid substitution. (B) Heatmap of  
 733 mutations in SARS-CoV-2 nsp12 (RNA dependent RNA polymerase) among  
 734 immunocompromised patients who received remdesivir and had a post-treatment sample  
 735 (n=7). 17 patients had a post-treatment remdesivir sample; of these, 7 had *de novo* non-  
 736 synonymous mutations in nsp12. In both (A) and (B), the day of infection is indicated to the left  
 737 of heatmap, and the day of treatment is indicated to the right.

738

739 **Table 2.** *De novo* mutations identified in immunocompromised patients after treatment with  
 740 SARS-CoV-2 antivirals — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023  
 741

Treatment	Substitution	Number of patients	Gene/domain	Known resistance mutation	
<b>Monoclonal</b>					
<i>spike</i>	L10P	1	S/none	No	742
	L84P	1	S/NTD	No	743
	H146Q	1	S/NTD	No	744
	W152R	1	S/NTD	No	745
	W152L	1	S/NTD	No	748
	G261R	1	S/NTD	No	749
	N354K	1	S/RBD	No	750
	S371P	1	S/RBD	Yes	751
	S371F	1	S/RBD	Yes	752
	K444T	3	S/RBD	Yes	753
	K444N	7	S/RBD	Yes	754
	V445F	1	S/RBD	Yes	755
	V445A	1	S/RBD	Yes	756
	G446R	2	S/RBD	Yes	757
	G446S	1	S/RBD	Yes	758
	N448D	1	S/RBD	Yes	759
	L452M	1	S/RBD	Yes	760
	T547K	1	S/none	No	761
	A570T	1	S/none	No	762
	V595I	1	S/none	No	763
	G652R	1	S/none	No	764
	T747I	1	S/none	No	765
	R765S	1	S/none	No	766
	T791I	1	S/FP	No	767
D936Y	1	S/HR1	No	768	
S1003I	2	S/none	No	769	
F1042I	1	S/none	No	770	
H1048Y	1	S/none	No	771	
V1228L	1	S/none	No	772	
S1252F	1	S/none	No	773	
D1257V	1	S/none	No	774	
<b>Remdesivir</b>					
<i>nsp12</i>	E136V	1	ORF1b/nsp12	No	775
	V166L	1	ORF1b/nsp12	Yes	776
	S364P	1	ORF1b/nsp12	No	777
	A379P	1	ORF1b/nsp12	No	778
	V792I	1	ORF1b/nsp12	Yes	779
	M794I	2	ORF1b/nsp12	No	780
	K798I	1	ORF1b/nsp12	No	781
	C799Y	1	ORF1b/nsp12	Yes	782
	W800L	1	ORF1b/nsp12	No	783
	T896K	1	ORF1b/nsp12	No	784

780 \* Two patients had a post-treatment sample following receipt of convalescent plasma; none  
 781 had *de novo* non-synonymous mutations. Four patients had a post-treatment molnupiravir  
 782 sample, and all four had a high number of nucleotide substitutions (ranging from 97 to >500)  
 783 dispersed throughout the genome.

784 **Supplemental Table 1.** List of qualifying medications that are immunosuppressive,  
785 immunomodulatory, or myelosuppressive (see attached)  
786

787 **Supplemental Table 2.** Clinical, demographic, viral, and specimen data for enrolled patients  
788 (see attached)  
789

790 **Supplemental Table 3.** Output of Cox proportional hazards model for time to last positive SARS-  
791 CoV-2 rRT-PCR test  
792

	Hazard Ratio	Lower 95% CI	Upper 95% CI
B cell dysfunction vs. Autoimmune/Autoinflammatory	0.315	0.154	0.644
Post-SOT/HSCT vs. Autoimmune/Autoinflammatory	0.597	0.38	0.939
AIDS vs. Autoimmune/Autoinflammatory	0.282	0.08	0.996
Malignancy vs. Autoimmune/Autoinflammatory	0.582	0.312	1.085
Age	0.994	0.981	1.008
Sex - Male vs. Female	1.035	0.7	1.529
Black vs. White	0.852	0.55	1.32
Hispanic vs. White	2.049	1.002	4.191
Other / Unknown vs. White	0.671	0.269	1.672
One or More Dose of Vaccine vs. Not Vaccinated	1.653	0.775	3.527
Baseline Antiviral Use - Yes vs. No	0.878	0.572	1.35

793  
794 \* Variables included in the final model were immunocompromised group, age, sex, race,  
795 vaccination status, and receipt of antiviral drug at baseline (see Methods).  
796

797 **Supplemental Table 4.** Within-host divergence rates by gene for synonymous, nonsynonymous,  
 798 and stop-codon mutations  
 799

Gene	Mutation type	Zero count (%)	Median divergence rate	IQR	p-value*
<b>ORF1a</b>	Non-synonymous	51 (58%)	0	1.34E-06	3.56E-06
	Stop	85 (97%)	0	0	1
	Synonymous	37 (42%)	1.89E-06	2.24E-05	7.37E-09
<b>ORF1b</b>	Non-synonymous	47 (53%)	0	1.82E-06	7.55E-07
	Stop	87 (99%)	0	0	1
	Synonymous	59 (67%)	0	1.22E-06	8.11E-05
<b>S</b>	Non-synonymous	51 (58%)	0	8.94E-06	3.56E-06
	Stop	87 (99%)	0	0	1
	Synonymous	53 (60%)	0	4.07E-05	7.76E-06
<b>ORF3a</b>	Non-synonymous	82 (93%)	0	0	1
	Stop	86 (98%)	0	0	1
	Synonymous	82 (93%)	0	0	1
<b>E</b>	Non-synonymous	87 (99%)	0	0	1
	Stop	88 (100%)	0	0	NA
	Synonymous	86 (98%)	0	0	1
<b>M</b>	Non-synonymous	77 (88%)	0	0	0.11571878
	Stop	88 (100%)	0	0	NA
	Synonymous	83 (94%)	0	0	1
<b>ORF6</b>	Non-synonymous	85 (97%)	0	0	1
	Stop	88 (100%)	0	0	NA
	Synonymous	85 (97%)	0	0	1
<b>ORF7a</b>	Non-synonymous	82 (93%)	0	0	1
	Stop	88 (100%)	0	0	NA
	Synonymous	87 (99%)	0	0	1
<b>ORF8</b>	Non-synonymous	81 (92%)	0	0	0.67482814
	Stop	85 (97%)	0	0	1
	Synonymous	88 (100%)	0	0	NA
<b>N</b>	Non-synonymous	75 (85%)	0	0	0.04985083
	Stop	87 (99%)	0	0	1
	Synonymous	82 (93%)	0	0	1

800  
 801  
 802 \* Wilcoxon signed rank test for difference in divergence rate (per site per day) vs. zero,  
 803 Bonferroni adjusted p-value



804 **Supplemental Table 5.** Consensus mutations in SARS-CoV-2 spike among 5  
 805 immunocompromised patients with  $\geq 2$  sequenced specimens and  $>56$  days of RT-PCR positivity  
 806

Patient	Amino acid substitution	Spike domain*	Peak frequency (patient)	Date of peak frequency (patient)	Peak frequency (global)	Date of peak frequency (global)
EV084	W64R	NTD	99%	6/2022	1%	6/2022
EV022	D80G	NTD	91%	6/2022	1%	4/2021
EV022	F157L	NTD	70%	6/2022	18%	2/2023
EV009	S255P	NTD	99%	2/2023	<1%	2/2023
EV009	R346T	RBD	99%	1/2023	94%	4/2023
EV084	K356R	RBD	100%	7/2022	<1%	11/2021
EV022	L368I	RBD	65%	4/2022	90%	4/2023
EV022	S371P	RBD	100%	7/2022	<1%	1/2022
EV022	S371F	RBD	100%	7/2022	97%	11/2022
EV084	T376A	RBD	82%	5/2022	97%	7/2023
EV022	K444N	RBD	100%	6/2022	2%	11/2022
EV138	K444N	RBD	100%	9/2022	2%	11/2022
EV138	G446R	RBD	89%	8/2022	<1%	2/2023
EV009	G446D	RBD	100%	10/2022	<1%	1/2023
EV009	N450D	RBD	99%	7/2022	3%	11/2022
EV084	N450D	RBD	99%	6/2022	3%	11/2022
EV022	L452M	RBD	100%	7/2022	2%	6/2022
EV022	L455F	RBD	70%	6/2022	<1%	8/2020
EV084	I569T	SD1/SD2	99%	6/2022	<1%	7/2023
EV022	R765L	none	71%	6/2022	<1%	2/2020
EV022	T791I	FP	95%	7/2022	1%	7/2021
EV022	D936Y	HR1	99%	7/2022	2%	4/2020
EV009	D1139N	none	94%	1/2023	<1%	10/2020

807  
 808 \* NTD = N terminal domain, RBD = receptor binding domain, FP = fusion peptide, HR = heptad  
 809 repeat.

810  
 811 † Global mutational data from GISAID, February 2020 – April 2022  
 812


813 **Supplemental Table 6. Neutralization FRNT50 of patient-derived viruses with serum pools**  
 814

Patient and Sample Day	New Spike Mutations *	Pre-Vax Pool 1 <sup>†</sup>	Post-Vax Pool 1 <sup>†</sup>	Pre-Vax Pool 2 <sup>†</sup>	Post-Vax Pool 2 <sup>†</sup>	Pre-Vax Pool 3 <sup>†</sup>	Post-Vax Pool 3 <sup>†</sup>
EV138 day 20 (19 days post-bebtelovimab)	–	68	166	38	278	574	992
EV138 day 63 (62 days post-bebtelovimab)	K444N, G446R	16	45	23	114	137	302
<i>Fold Change</i> #	–	-4.25	-3.7	-1.7	-2.4	-4.2	-3.3
EV009 day 91	R346T	103	111	190	13	47	44
<i>Fold Change</i> #		ND	ND	ND	ND	ND	ND
EV022 day 13	–	15	45	44	92	91	230
EV022 day 82 (14 days post-bebtelovimab)	K444N, L452M	13	33	53	114	63	253
<i>Fold Change</i> #	–	-1.2	-1.4	0.8	0.8	-1.4	0.9

815  
 816  
 817 Abbreviations: FRNT, Focus reduction neutralization test  
 818 \* New mutations at >50% frequency relative to the initial sample from the same patient  
 819 <sup>†</sup> Three pools of matched pre- and post-bivalent vaccination sera from xx individuals (pool 1), xx  
 820 individuals (pool 2), and xx individuals (pool 3)  
 821 # Fold change measured as the absolute reduction in serum neutralization in a patient's evolved  
 822 virus relative to their initial virus

823  
 824  
 825

826




827

828

829 **Supplemental Figure 1.** Flow diagram of enrolled patients indicating patients and data included


830 in each analysis. iSNV = intrahost single nucleotide variants.



831  
832


833 **Supplemental Figure 2.** Plots show total (solid line, closed circles) and subgenomic N (dotted  
834 line, open circles) RNA viral load in serial specimens (day of infection, x-axis) for each of 16  
835 immunocompromised patients who had detectable viral RNA in  $\geq 2$  specimens spanning  $\geq 21$   
836 days. Lines and points are color coded by immunocompromised group: B cell dysfunction,  
837 purple; solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT), teal; AIDS,  
838 blue; non-B cell malignancy, pink; autoimmune/autoinflammatory, orange.  
839

840



841

842 **Supplemental Figure 3.** Diagram identifying 16 patients with prolonged infection; defined as  
 843 patients who had  $\geq 2$  sequenced specimens with rRT-PCR Ct  $\leq 32$  spanning  $\geq 21$  days. Lines and  
 844 points are color-coded by immunocompromised group: B cell dysfunction, purple; solid organ  
 845 transplant (SOT) or hematopoietic stem cell transplant (HSCT), teal; AIDS, blue; non-B cell  
 846 malignancy, pink; autoimmune/autoinflammatory, orange. Filled circles indicate specimens  
 847 with rRT-PCR Ct  $\leq 32$  and x indicate specimens with rRT-PCR Ct  $> 32$ .




848

849

850 **Supplemental Figure 4.** Depth of coverage in sequenced specimens. Plots showing (A) number  
851 of specimens (y-axis) with fraction of the genome (x-axis) covered at the indicated depths (lines,  
852 legend) and (B) read depth by genomic position (sliding window) for 140 specimens with rRT-  
853 PCR Ct  $\leq 32$ . Plots showing (C) number of specimens (y-axis) with fraction of the genome (x-axis)  
854 covered at the indicated depths (lines, legend) and (D) read depth by genomic position (sliding  
855 window) for 52 specimens with rRT-PCR Ct  $> 32$ .

856




857

858

859 **Supplemental Figure 5.** Number of intrahost single nucleotide variants (iSNV) identified at 2-  
860 100% frequency (y-axis) per specimen (point) as a function of total SARS-CoV-2 RNA rRT-PCR Ct  
861 value. The regression line (blue), 95% confidence interval for the regression (shaded area), and  
862 the equation and R<sup>2</sup> for the regression are indicated. The outlier point with over 500 iSNV  
863 represents a single specimen from a patient previously treated with molnupiravir.

864



865

866 **Supplemental Figure 6.** Plot of SARS-CoV-2 total RNA rRT-PCR Ct values for the 115 patients  
867 receiving indicated antiviral treatments. Lines and points are color-coded by  
868 immunocompromised group: B cell dysfunction, purple; solid organ transplant (SOT) or  
869 hematopoietic stem cell transplant (HSCT), teal; AIDS, blue; non-B cell malignancy, pink;  
870 autoimmune/autoinflammatory, orange.